Founded in 2007, H.A.C. Pharma is a private, PE-backed European specialty pharmaceutical platform dedicated to delivering therapies for patients facing conditions with limited treatment options.
H.A.C. Pharma has earned the trust of international partners by licensing or acquiring, registering, and commercializing their medicines across Europe. This successful track record is built on a structured approach involving healthcare professionals, medical societies, and regulatory authorities to ensure optimal patient access.
H.A.C. Pharma’s mission is to deliver essential medicines that matter – safe, effective and meaningful – while ensuring their proper therapeutic use to improve patients’ lives.

H.A.C. Pharma offers unique end-to-end capabilities for launching high-therapeutic value medicines across Europe, particularly in conditions with limited treatment alternatives. By managing all key functions internally, including regulatory affairs, market access, medical science liaison, pharmacovigilance, medical information, and commercial activities, H.A.C. Pharma ensures timely implementation, agility and quality.
H.A.C. Pharma’s in-house regulatory team can manage European registration through various procedures, including orphan designation, centralized procedures and early access programs.